Home › Funds › JANUS INVESTMENT FUND › Janus Henderson Venture Fund
Fund family: JANUS INVESTMENT FUND · Filed by JANUS INVESTMENT FUND (CIK 277751) · SEC series S000010488
Share classes and tickers: JANVX (C000083533), JAVTX (C000028950), JVTAX (C000100475), JVTCX (C000100476), JVTIX (C000100477), JVTNX (C000114881), JVTSX (C000100478)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 941 with, 3 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 1 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as JANUS INVESTMENT FUND’s manager page (17,858 ballot items across 30 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | JANUS INVESTMENT FUND | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 95.2% | 916 | 97.2% | 15,061 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 3.6% | 392 |
Each ballot item this fund voted is set against the votes of the other JANUS INVESTMENT FUND funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most JANUS INVESTMENT FUND funds on 3 items (1.9% of the 161 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most JANUS INVESTMENT FUND funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Revolution Medicines, Inc. | 2026-06-18 | To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis Borisy | Withhold | FOR — 7 of 9 JANUS INVESTMENT FUND funds | Against | Passed (calculated), 79.1% support |
| BridgeBio Pharma, Inc. | 2026-06-22 | To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares. | Against | FOR — 4 of 5 JANUS INVESTMENT FUND funds | Against | Approved, 82.9% support |
| BridgeBio Pharma, Inc. | 2026-06-22 | To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly ele | Withhold | FOR — 4 of 5 JANUS INVESTMENT FUND funds | Against | Passed (calculated), 80.1% support |
Download all 3 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 84.9% of this fund’s 944 such votes could be given a sector; the other 143 (15.1%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 232 | 1 | 0.4% |
| Industrials | 152 | 0 | 0.0% |
| Consumer Discretionary | 137 | 1 | 0.7% |
| Technology | 124 | 1 | 0.8% |
| Finance | 79 | 0 | 0.0% |
| Energy | 21 | 0 | 0.0% |
| Miscellaneous | 16 | 0 | 0.0% |
| Consumer Staples | 14 | 0 | 0.0% |
| Telecommunications | 14 | 0 | 0.0% |
| Real Estate | 12 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 629 | 0 |
| Audit-related | 122 | 0 |
| Say-on-Pay | 107 | 0 |
| Compensation | 42 | 0 |
| Corporate Governance | 23 | 1 |
| Capital Structure | 15 | 0 |
| Extraordinary Transactions | 11 | 0 |
| Shareholder Rights and Defenses | 3 | 0 |
| Other | 2 | 0 |
| Other Social Issues | 2 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Glaukos Corporation | May 28, 2026 | $159M | 4 | 0 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $80M | 11 | 0 |
| Casey's General Stores, Inc. | September 3, 2025 | $70M | 15 | 1 |
| Perimeter Solutions, Inc. | May 28, 2026 | $63M | 10 | 0 |
| SS&C Technologies Holdings, Inc. | May 20, 2026 | $62M | 6 | 0 |
| Revolution Medicines, Inc. | June 18, 2026 | $61M | 4 | 0 |
| Sensient Technologies Corporation | April 23, 2026 | $56M | 11 | 0 |
| OSI Systems, Inc. | December 11, 2025 | $51M | 8 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| September 3, 2025 | Casey's General Stores, Inc. | Shareholder proposal regarding Scope 3 greenhouse gas reduction targets. Shareholder proposal | Against | For |
| May 13, 2026 | ICU Medical, Inc. | To approve, on an advisory basis, a stockholder proposal to establish a 10% stockholder special meeting right. Shareholder proposal | Against | For |
| May 5, 2026 | Tyler Technologies, Inc. | Shareholder Proposal Regarding Political Spending. Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (2 in 2025-2026), and how the fund voted the items on its ballot.
957 ballot items at 123 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Janus Henderson Venture Fund (JANVX) voted at 123 shareholder meetings of 120 companies, on 957 ballot items in all. Where management made a recommendation, the fund followed it on 99.7% of the items and voted against it 3 times. Its most frequent area of disagreement was corporate governance (1 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals less often than JANUS INVESTMENT FUND's funds as a whole (95.2% against 97.2%). It voted differently from most JANUS INVESTMENT FUND funds on 3 items. 2 of its meetings were contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of JANUS INVESTMENT FUND’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.